High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
Paul J. Hengeveld(Erasmus MC), Anton W. Langerak(Erasmus MC), Mark‐David Levin(Albert Schweitzer Hospital), Lina van der Straten(Erasmus MC), Peter E. Westerweel(Albert Schweitzer Ziekenhuis), Melissa Rijken(Erasmus MC Cancer Institute), Jorn L. J. C. Assmann(Erasmus MC), Arnon P. Kater(Amsterdam University Medical Centers), P. Martijn Kolijn(Erasmus MC), Jeroen Demmers(Erasmus MC), Peter J.M. Valk(Erasmus MC Cancer Institute), Wouter Doff(Erasmus MC), Henk Jan Boiten(Erasmus MC), Kirsten J. Gussinklo(Erasmus MC Cancer Institute), Laura M. Faber(Red Cross Hospital), Julie Dubois(University of Fribourg)
Cited by 5
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
|Nature|2013|2.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907